The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
KellyK., CrowleyJ., BunnP.A.A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) trial. Proc Am Soc Clin Oncol.1999; 18: 461a.
2.
LaohavinijS., MaoleekoonpairojS., CheirsilpaA.Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer. Lung Cancer.1999; 26: 175–85.
3.
KosmidisA., MylonakisN., FountzilasG.Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study. Ann Oncol.1997; 8: 697–9.
4.
HelsingM., ThaningL., SederholmC.Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-lung cancer: A phase II multicentre trial. Lung Cancer.1999; 24: 107–13.
5.
HainsworthJ.D., UrbaW.J., HonJ.K.One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer.1998; 34: 654–8.
6.
LangerC.J., LeightonJ.C., ComisR.L.Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol.1995; 13: 1860–70.
7.
JohnsonD.H., PaulD.M., HandeK.R.Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol.1996; 14: 2054–60.
8.
ChoyH., AkerleyW., SafranH.Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol.1998; 16: 3316–22.
9.
CalvertA.H., NewellD.R., GumbrellL.A.Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol.1989; 7: 1748–56.
10.
CockcroftD.W., GaultM.H.Prediction of creatinine clearance from serum creatinine. Nephron.1976; 16: 31–41.
11.
JelliffeR.W.Creatinine clearance: Bedside estimate. Ann Intern Med.1973; 79: 604–5.
12.
WaddellJ.A., HannanL.C., EchevarriaK.L.Detection of prescribing errors in calvert formula dosing of carboplatin [abstract]. J Am Pharm Assoc.1999; 39: 246.
13.
CheungY.W., CradockJ.C., VishnuvajjalaB.R.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–30.
14.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
15.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
16.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
17.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
18.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(suppl 1): 26–31.
19.
DuBoisA., VachW., KiechleM.Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology.1996; 53(suppl 1): 46–50.
20.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–58.
American Society of Clinical Oncology.American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.1994; 12: 2471–508.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
26.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of anti-neoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
27.
SteinM.E., DrumeaK., Abu-RasmiR.Taxol-induced cellulitis after extravasation: a rarely reported event [letter]. Am J Clin Oncol.1997; 20: 540.
28.
BicherA., LevenbackC., BurkeT.W.Infusion site soft-tissue injury after paclitaxel administration. Cancer.1995; 76: 116–20.
29.
AjaniJ.A., DoddL.G., DaughertyK.Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst.1994; 86: 51–3.
30.
KintzelP.E., DorrR T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
31.
VenookA.P., EgorinM.J., RosnerG.L.Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol.1998; 16: 1811–9.
